SciSparc Ltd
Company Profile
Business description
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company’s operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
Contact
20 Raul Wallenberg Street
Tower A, 2nd Floor
Tel Aviv6971916
ISRT: +972 37175777
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3
Stocks News & Analysis
stocks
ASX listed bank overvalued despite strong earnings
stocks
After earnings, is Amazon a buy, a sell, or fairly valued?
stocks
ASX retail share expected to recover despite choppy conditions
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.40 | 14.50 | 0.16% |
| CAC 40 | 8,056.38 | 56.19 | -0.69% |
| DAX 40 | 24,350.28 | 11.65 | 0.05% |
| Dow JONES (US) | 49,704.47 | 95.31 | 0.19% |
| FTSE 100 | 10,269.43 | 36.36 | 0.36% |
| HKSE | 26,406.84 | 13.13 | 0.05% |
| NASDAQ | 26,274.13 | 27.05 | 0.10% |
| Nikkei 225 | 62,417.88 | 295.77 | -0.47% |
| NZX 50 Index | 13,210.48 | 35.35 | 0.27% |
| S&P 500 | 7,412.84 | 13.91 | 0.19% |
| S&P/ASX 200 | 8,701.80 | 11.50 | 0.13% |
| SSE Composite Index | 4,225.02 | 45.07 | 1.08% |